Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04917809	Phase II	Erdafitinib	A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer	Recruiting	USA	0
NCT05564416	Phase II	Erdafitinib Atezolizumab + Erdafitinib	Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial	Withdrawn		0
NCT05627063	Phase I	ABSK121	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT02846766	Phase II	Lenvatinib	Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling	Withdrawn	USA	0
NCT04972253	Phase I	Infigratinib	Phase I BLASST-3 Trial ((BLASST)-3)	Withdrawn		0
NCT06160752	Phase I	TYRA-200	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)	Recruiting	USA	0
NCT04096417	Phase II	Pemigatinib	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Active, not recruiting	USA	0
NCT02299141	Phase I	Nintedanib	Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT02558348	Phase Ib/II	Anlotinib	Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	Terminated	USA	0
NCT02706691	Phase II	Infigratinib	Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer	Terminated	USA	0
NCT04092673	Phase Ib/II	Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin	Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)	Recruiting	USA	0
NCT04233567	Phase II	Infigratinib	Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	Active, not recruiting	USA	0
NCT01975701	Phase II	Infigratinib	A Phase 2 Study of BGJ398 in Patients With Recurrent GBM	Completed	USA \| NLD \| ESP \| BEL \| AUS	1
NCT02925234	Phase II	Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT02608125	Phase I	PRN1371	A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma	Terminated	USA \| ESP	0
NCT02393248	Phase Ib/II	Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Terminated	USA	1
NCT02160041	Phase II	Infigratinib	BGJ398 for Patients With Tumors With FGFR Genetic Alterations	Terminated	USA	0
NCT03344536	Phase Ib/II	Debio 1347 + Fulvestrant	A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer	Completed	USA	0
NCT01948297	Phase I	Debio 1347	Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations	Terminated	USA \| ESP	3
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Active, not recruiting	USA	0
NCT03238196	Phase I	Erdafitinib + Fulvestrant + Palbociclib	Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer	Active, not recruiting	USA	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT02872714	Phase II	Pemigatinib	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	3
NCT04424966	Phase 0	Infigratinib	Infigratinib in Recurrent High-Grade Glioma Patients	Terminated	USA	0
NCT04463771	Phase II	Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab	Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204)	Recruiting	USA \| ITA \| FRA \| DEU \| BEL	3
NCT04003610	Phase II	Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib	Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	7
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT05216120	Phase II	Pemigatinib	Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas	Withdrawn	USA	0
NCT01004224	Phase I	Infigratinib	A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| AUT \| AUS	6
NCT02529553	Phase I	LY3076226	A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Completed	USA \| CAN	0
NCT04565275	Phase Ib/II	ICP-192	A Study of ICP-192 in Patients With Advanced Solid Tumors	Recruiting	USA \| AUS	0
NCT02312804	Phase I	Paclitaxel Carboplatin Infigratinib	Ph Ib/BGJ398/Cervix and Other Solid Tumors	Withdrawn		0
NCT04003623	Phase II	Pemigatinib	Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)	Terminated	USA	0
NCT01928459	Phase I	Alpelisib + Infigratinib	Phase 1b Trial of BGJ398/BYL719 in Solid Tumors	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT04601857	Phase II	Futibatinib + Pembrolizumab	Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	USA \| FRA \| ESP	0
NCT04504331	Phase I	Fulvestrant + Infigratinib + Palbociclib Infigratinib + Tamoxifen	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Terminated	USA	0
NCT04045613	Phase Ib/II	Derazantinib Atezolizumab + Derazantinib	Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS	5
NCT02747797	Phase II	Lucitanib	Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations	Withdrawn	USA	0
NCT01831726	Phase II	Dovitinib	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	USA	0
NCT02952573	Phase II	Dexamethasone + Erdafitinib	Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement	Terminated	CAN	0
NCT04294277	Phase II	Pemigatinib	Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS)	Terminated	ITA	0
NCT04172675	Phase II	Erdafitinib Gemcitabine Mitomycin C	A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	9
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	7
NCT02401542	Phase Ib/II	Docetaxel + Vofatamab Vofatamab Docetaxel	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)	Terminated	USA \| ITA \| GBR \| ESP	5
NCT05242822	Phase I	KIN-3248	A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	Active, not recruiting	USA \| ESP	4
NCT03822117	Phase II	Pemigatinib	Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU	5
NCT03934372	Phase Ib/II	Ponatinib	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Recruiting	NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT04604132	Phase Ib/II	Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab	Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	7
NCT04595747	Phase II	Rogaratinib	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT03210714	Phase II	Erdafitinib	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT02546661	Phase I	Danvatirsen + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab	Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)	Active, not recruiting	USA \| GBR \| FRA \| ESP \| CAN	0
NCT04088188	Phase I	Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib	Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma	Active, not recruiting	USA	0
NCT05363605	Phase Ib/II	225Ac-FPI-1966 + Vofatamab	A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours	Terminated	USA \| AUS	0
NCT04483505	Phase I	Fulvestrant + Palbociclib + Rogaratinib	Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST)	Completed	ESP	0
NCT03834220	Phase II	Debio 1347	Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)	Terminated	USA \| NLD \| GBR \| FRA \| ESP \| AUT \| AUS	16
NCT05316155	Phase I	Erdafitinib	Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer	Recruiting	USA \| NLD \| ESP \| DEU	1
NCT02657486	Phase 0	Infigratinib	BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder	Active, not recruiting	USA	0
NCT04197986	Phase III	Infigratinib	Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations	Terminated	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL	2
NCT05544552	Phase Ib/II	TYRA-300	Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)	Recruiting	USA \| FRA \| ESP \| AUS	0
NCT05244551	Phase I	ABSK061	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT02052778	Phase Ib/II	Futibatinib	A Study of TAS-120 in Patients With Advanced Solid Tumors	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	4
NCT05267106	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	2
NCT06302621	Phase I	Afatinib + Pemigatinib	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors	Not yet recruiting	USA	0
NCT05253807	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)	Completed	USA \| ITA \| FRA \| ESP \| DEU	0
NCT05614739	Phase I	LOXO-435 + Pembrolizumab LOXO-435	A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	Recruiting	USA \| NLD \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	3
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT03732703	Phase Ib/II	Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide	Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)	Unknown status	USA	0
NCT04923126	Phase Ib/II	PD-0325901	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT04963153	Phase I	Enfortumab vedotin-ejfv + Erdafitinib	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	Recruiting	USA	0
NCT01976741	Phase I	Rogaratinib	Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor	Completed	USA \| FRA \| ESP \| DEU	3
NCT04040725	Phase II	Rogaratinib	Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression	Withdrawn		0
NCT06263153	Phase II	Durvalumab + Futibatinib	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	Not yet recruiting	USA	0
NCT03473756	Phase Ib/II	Atezolizumab Atezolizumab + Rogaratinib	Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| AUT	2
NCT03410693	Phase II	Docetaxel Vinflunine Paclitaxel Rogaratinib	Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	18
NCT03088059	Phase II	Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil	Biomarker-based Study in R/M SCCHN (UPSTREAM)	Active, not recruiting	ITA \| GBR \| FRA \| ESP \| BEL	0
NCT03517956	Phase I	Copanlisib + Rogaratinib	Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)	Completed	USA \| ESP \| DEU \| BEL	2
NCT04189445	Phase II	Futibatinib	Futibatinib in Patients With Specific FGFR Aberrations	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	7
NCT03611868	Phase Ib/II	APG-115 + Pembrolizumab	A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors	Recruiting	USA \| AUS	0

Gene Detail

Contact

Filtering

Sorting